comparemela.com
Home
Live Updates
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma : comparemela.com
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational... | April 23, 2023
Related Keywords
Russia
,
Monash
,
South Australia
,
Australia
,
Ukraine
,
Sydney
,
New South Wales
,
Melbourne
,
Victoria
,
Neoadjuvant Po
,
Meredith Mckean
,
Anthony Joshua
,
Mark Shackleton
,
Darrin Beaupre
,
Yujiros Hata
,
Werner Helicase
,
While The Company
,
St Vincent Hospital Garvan Medical Research Institute
,
Pfizer
,
Nasdaq
,
Vincent Hospital Sydney
,
Head Of The Department Medical Oncology
,
Exchange Commission
,
Novartis
,
Biosciences Inc
,
Company Annual Report On Form
,
Kinghorn Cancer Centre
,
Skin Cancer Research
,
Sarah Cannon Research
,
Chief Medical Officer
,
Data Update
,
Crizotinib Combination
,
Overall Response Rate
,
Disease Control Rate
,
Progression Free Survival
,
Typec Meeting Supports Initiation
,
Potential Registrational
,
Adjuvant Primary
,
Medical Oncology
,
Garvan Medical Research Institute
,
Hospital Sydney Limited
,
Patient Population
,
Eastern Time
,
Sarah Cannon Research Institute
,
Skin Cancer Trials
,
Chief Executive Officer
,
Investor Relations
,
Private Securities Litigation Reform Act
,
Annual Report
,
Vice President
,
Chief Financial Officer
,
Ideaya Biosciences
,
Nc Stock Exchange
,
News
,
Information
,
Press Release
,
Onfirmed
,
Verall
,
Response
,
Gate
,
F
,
Disease
,
Control
,
End
,
Comedian
,
Ifs
,
Months
,
N
,
0
,
Valuable
,
Um
,
Atientsbased
,
Fda
,
Initiating
,
Hase Idya Us45166a1025
,
comparemela.com © 2020. All Rights Reserved.